Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.77−0.02 (-2.23%)
Close on Nov 20, 2026Market cap $99.29MP/E –Yield –
Organogenesis free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Organogenesis's free cash flow for the twelve months ending Jun 30, 2026 was $20.84M. For fiscal 2025 it was -$24.46M, down 685.7% from the year before. The highest annual figure on record is $30.76M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.46M | -685.7% |
| FY2024 | Dec 31, 2024 | $4.18M | -36.3% |
| FY2023 | Dec 31, 2023 | $6.55M | – |
| FY2022 | Dec 31, 2022 | -$9.04M | -129.4% |
| FY2021 | Dec 31, 2021 | $30.76M | – |
| FY2020 | Dec 31, 2020 | -$12.21M | – |
| FY2019 | Dec 31, 2019 | -$39.51M | – |
| FY2018 | Dec 31, 2018 | -$62.49M | – |
| FY2017 | Dec 31, 2017 | -$5.92M | – |
| FY2016 | Dec 31, 2016 | -$6.23M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.75M | – |
| Q1 FY2026 | Mar 31, 2026 | $17.98M | – |
| Q4 FY2025 | Dec 31, 2025 | $34.77M | +358.9% |
| Q3 FY2025 | Sep 30, 2025 | $844.00K | -86.2% |
| Q2 FY2025 | Jun 30, 2025 | -$36.51M | -1377.5% |
| Q1 FY2025 | Mar 31, 2025 | -$23.56M | – |
| Q4 FY2024 | Dec 31, 2024 | $7.58M | +3.9% |
| Q3 FY2024 | Sep 30, 2024 | $6.13M | -43.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.86M | +149.2% |
| Q1 FY2024 | Mar 31, 2024 | -$12.38M | – |
| Q4 FY2023 | Dec 31, 2023 | $7.29M | – |
| Q3 FY2023 | Sep 30, 2023 | $10.76M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.15M | -71.5% |
| Q1 FY2023 | Mar 31, 2023 | -$12.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.86M | -122.5% |
| Q3 FY2022 | Sep 30, 2022 | -$4.95M | -144.4% |
| Q2 FY2022 | Jun 30, 2022 | $4.03M | -69.4% |
| Q1 FY2022 | Mar 31, 2022 | -$5.26M | – |
| Q4 FY2021 | Dec 31, 2021 | $12.72M | -28.5% |
| Q3 FY2021 | Sep 30, 2021 | $11.15M | +269.1% |
| Q2 FY2021 | Jun 30, 2021 | $13.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.26M | – |
| Q4 FY2020 | Dec 31, 2020 | $17.80M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.53M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.05M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.88M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.77M | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.52M | – |
See a number that looks wrong?